About Verve Therapeutics
Verve Therapeutics is a company based in Cambridge (United States) founded in 2018 by J Keith Joung, Issi Rozen, and Burt Adelman was acquired by Lilly in June 2025. It operates as a HealthTech. Verve Therapeutics has raised $215.5 million across 3 funding rounds from investors including Lilly, Citadel and Janus Henderson Investors. The company has 255 employees as of December 31, 2023. Verve Therapeutics offers products and services including VERVE-102 and VERVE-201. Verve Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 255 as on 31 Dec, 2023
- Founders J Keith Joung, Issi Rozen, Burt Adelman
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Verve Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Verve Therapeutics
Verve Therapeutics offers a comprehensive portfolio of products and services, including VERVE-102 and VERVE-201. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Gene editing therapy targeting PCSK9 for LDL-C reduction.
Gene editing solution addressing cardiovascular disease risk factors.
Unlock access to complete
Unlock access to complete
Funding Insights of Verve Therapeutics
Verve Therapeutics has successfully raised a total of $215.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $94 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $94.0M
-
First Round
First Round
(07 May 2019)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series B - Verve Therapeutics | Valuation | Wellington , Casdin Capital | |
| Jun, 2020 | Amount | Series A - Verve Therapeutics | Valuation | Google Ventures | |
| May, 2019 | Amount | Series A - Verve Therapeutics | Valuation | Google Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Verve Therapeutics
Verve Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Citadel and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Verve Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Verve Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Verve Therapeutics Comparisons
Competitors of Verve Therapeutics
Verve Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Verve Therapeutics
Frequently Asked Questions about Verve Therapeutics
When was Verve Therapeutics founded?
Verve Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Verve Therapeutics located?
Verve Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Verve Therapeutics a funded company?
Verve Therapeutics is a funded company, having raised a total of $215.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $58.5M, raised on May 07, 2019.
How many employees does Verve Therapeutics have?
As of Dec 31, 2023, the latest employee count at Verve Therapeutics is 255.
What does Verve Therapeutics do?
Verve Therapeutics is dedicated to combating cardiovascular disease (CVD), the leading cause of death worldwide, through innovative single-course gene editing medicines. Solutions are developed to inactivate specific genes in the liver that contribute to CVD risk. The pipeline includes programs like VERVE-102 and VERVE-201, targeting conditions such as heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Advances in human genetics and gene editing technologies are leveraged to transform the treatment paradigm for hundreds of millions affected by atherosclerotic cardiovascular disease (ASCVD).
Who are the top competitors of Verve Therapeutics?
Verve Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Verve Therapeutics offer?
Verve Therapeutics offers VERVE-102 and VERVE-201.
Who are Verve Therapeutics's investors?
Verve Therapeutics has 15 investors. Key investors include Lilly, Citadel, Janus Henderson Investors, RA Capital, and Arch Venture Partners.